BridGene employs two strategies to develop covalent drugs:

1. Proprietary Chemoproteomics Platform IMTAC ^TM – develop “First-in-Class” covalent drugs for high-value yet hard-to-drug targets, including targets involving protein-protein interactions or containing shallow binding pockets. IMTAC ^TM combines cutting-edge technologies including covalent chemistry, chemical proteomics, and quantitative mass spectrometry.

2. Target-Orientated Discovery – applies our industry leading knowhow and expertise in covalent warheads to design and develop novel covalent drugs.